Drug Profile
Research programme: ddRNAi-based therapeutics - Benitec/Circuit Therapeutics
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Benitec Biopharma
- Developer Circuit Therapeutics
- Class DNA
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Pain in USA (PO)
- 03 Nov 2014 Early research in Pain in USA (PO)